This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Proactive: Race Oncology advances RNA epigenetics with FTO drug discovery at Monash
Race CEO Dr Daniel Tillett joins Proactive’s Tylah Tully to discuss the FTO drug discovery program the company has concluded at Monash University’s Fragment Platform (MFP).
Watch the full interview below and for the full news report via this link.